Omeros Q1 Earnings Call Highlights
Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
Omeros Corporation Reports First Quarter 2026 Financial Results
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade
4 Medical Product Stocks to Buy From a Challenging Industry
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
Omeros Corporation (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Brokerages
Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?
JPMorgan Chase & Co. Boosts Holdings in Omeros Corporation $OMER
Contrasting Omeros (NASDAQ:OMER) and Medtronic (NYSE:MDT)
Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates
Stock Traders Buy High Volume of Call Options on Omeros (NASDAQ:OMER)
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average – Here’s Why
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Reviewing Senestech (NASDAQ:SNES) & Omeros (NASDAQ:OMER)
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Omeros Announces First Commercial Sales of YARTEMLEA®
David Borges Sells 30,000 Shares of Omeros (NASDAQ:OMER) Stock
Omeros (NASDAQ:OMER) Trading Down 5.8% After Insider Selling
Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
Omeros prices transplant complication drug at $36,000 per dose
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
Omeros (NASDAQ:OMER) Hits New 12-Month High – Time to Buy?
Traders Purchase Large Volume of Call Options on Omeros (NASDAQ:OMER)
Why Omeros Stock Skyrocketed Today
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely
Gold Edges Lower; Omeros Shares Jump
FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication
US FDA approves Omeros' drug to treat dangerous transplant complication
FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of “Moderate Buy” from Brokerages
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript
Omeros Corporation Reports Third Quarter 2025 Financial Results
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
Breakout Momentum Plays You Need to Know About
Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case